LIPAC Oncology is a clinical-stage company based in Menlo Park, California, specializing in the development of precision targeted, locally delivered taxane technology for the treatment of various types of cancer, including Bladder Cancer, Upper Tract Urothelial Carcinoma, Stage II III Ovarian Cancer, Intraperitoneal Carcinoma, and Mesothelioma Malignant Pleural Effusion.
With a strong focus on addressing areas of significant unmet medical need, LIPAC Oncology's innovative pipeline of products aims to provide life-saving treatment options for cancer patients through breakthrough nano liposome-bound technology, offering localized tumor treatment.
Generated from the website